Spero Therapeutics, Inc. Forecast, price target & analysts
Spero Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Spero Therapeutics, Inc. Classifications & Recommendation:
Spero Therapeutics, Inc. Price Target
| Target Price | $5.10 |
| Price | $1.91 |
| Potential |
167.02%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Spero Therapeutics, Inc. 2026 .
The average Spero Therapeutics, Inc. target price is $5.10.
This is
167.02%
register free of charge
$5.25
174.87%
register free of charge
$5.05
164.40%
register free of charge
|
|
| A rating was issued by 9 analysts: 6 Analysts recommend Spero Therapeutics, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Spero Therapeutics, Inc. stock has an average upside potential 2026 of
167.02%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2031
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 47.98 | 6.02 |
| 53.77% | 87.46% | |
| Net Margin | -142.91% | -1,095.23% |
| 750.22% | 666.36% |
4 Analysts have issued a sales forecast Spero Therapeutics, Inc. 2025 . The average Spero Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Spero Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Spero Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2031
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.27 | -1.17 |
| 395.35% | 7.87% | |
| P/E | negative | |
| EV/Sales | 12.63 |
5 Analysts have issued a Spero Therapeutics, Inc. forecast for earnings per share. The average Spero Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Spero Therapeutics, Inc....
Current Spero Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 30 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Dec 20 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 02 2024 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 04 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 03 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 30 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Dec 20 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 02 2024 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Nov 18 2024 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Nov 15 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 04 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 03 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
